<DOC>
	<DOCNO>NCT02353429</DOCNO>
	<brief_summary>This prospective study evaluate activity safety toremifene patient primary recurrent sporadic DTs . Patients enrol histological confirmation DTs biopsy Patients start 60 mg daily dose-escalate 180 mg upon progression . Disease assessment perform contrast-enhanced MRI CT scan , pain evaluation visual analog scale ( VAS ) every 3 month first second year , twice yearly thereafter . Response evaluate either RECIST and/or symptomatic relief .</brief_summary>
	<brief_title>Toremifene Desmoid Tumor : Prospective Clinical Trial Identification Potential Molecular Targets</brief_title>
	<detailed_description>This prospective study evaluate activity safety toremifene patient primary recurrent sporadic DTs . Patients enrol histological confirmation DTs biopsy perform investigator institution pathological review tissue specimen obtain via needle biopsy surgical excision ( case recurrence ) perform elsewhere . A new biopsy perform amount tissue sufficient immunohistochemical analysis . Patients start 60 mg daily dose-escalate 180 mg upon progression . Disease assessment perform contrast-enhanced MRI CT scan , pain evaluation visual analog scale ( VAS ) every 3 month first second year , twice yearly thereafter . Response evaluate either RECIST and/or symptomatic relief .</detailed_description>
	<mesh_term>Fibromatosis , Aggressive</mesh_term>
	<mesh_term>Fibroma</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<criteria>Adult patient ( age &gt; 18 year ) primary locally recurrent , sporadic FAP associate , desmoid fibromatosis Histologically document diagnosis DF At least one measurable site disease CT MRI scan , previously embolised irradiated Progressive disease demonstrate contrastenhanced MRI CT scan Response Evaluation Criteria Solid Tumors ( RECIST ) Radiologic clinical evidence PD previous 6 month . Radiologic PD define accord RECIST ECOG Performance status : 02 Prior hormonal therapy , chemotherapy , molecular target therapy allow Adequate end organ function , define follow : total bilirubin &lt; 1.5 x ULN , SGOT SGPT &lt; 2.5 x UNL ( &lt; 5 x ULN hepatic metastasis present ) , creatinine &lt; 1.5 x ULN , ANC &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female patient reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug Life expectancy least 6 month Written , voluntary , informed consent . Previous history deep vein thrombosis Evidence prolong QTc &gt; 480 msec ( use Bazetts correction , formula : QTc = QT/âˆšRR ) history familial long QT syndrome Previous arrhythmia Clinically significant bradycardia Endometrial hyperplasia Hepatic insufficiency Other concurrent hormonal therapy , include hormonal contraceptive Patient receive investigational agent within 28 day first day study drug dose . Female patient pregnant breastfeed Patient severe and/or uncontrolled medical disease Patient know diagnosis human immunodeficiency virus ( HIV ) infection Patient receive chemotherapy within 4 week prior study entry Patient major surgery within 2 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>